Compared to those with an intrapartum diagnosis, women with a prenatal diagnosis of abnormally invasive placenta
Lost less blood loss during surgery
Mean difference (MD) −0.87; 95% CI, −1.5 to −0.23 (P=0.008)
Required fewer transfused units of
RBCs: MD −1.45; 95% CI, −2.9 to −0.04 (P=0.04)
FFP: MD −1.73; 95% CI, −3.3 to −0.2 (P=0.03)
MD -1.33 weeks; 95% CI, −2.23 to −0.43 (0.004)
There was no difference in risk of admission to an ICU, length of hospital stay or ICU stay
Prenatal diagnosis of abnormally invasive placenta was associated with a higher risk of urinary‐tract injury (odds ratio, 2.5; 95% CI, 1.3–4.6), due to the higher prevalence of placenta percreta in this group
Could include planned surgical approach, not necessarily unintentional error
Authors recognize study limitations including small number of included studies, some with less rigorous design (e.g. retrospective, non-randomized)
Limited data could result in the study being underpowered for less common outcomes
Percreta over-represented in the prenatal diagnosis group, leading to potential bias
Prenatal diagnosis of abnormally invasive placenta leads to fewer complications during and following delivery
Allows for delivery at expert centers
Larger studies required to determine best management approach
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan